Windlas Biotech Ltd

Windlas Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

The Sensex advanced 1.79% on 15 Apr 2026, yet Windlas Biotech Ltd outpaced the broader market with a 7.09% gain, touching an intraday high of Rs 875.45. This 5.15-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers signals a distinctly stock-specific rally rather than a mere market tailwind.

Windlas Biotech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics presented here reflect the company’s current position as of 12 April 2026, providing investors with the latest insights into its performance and outlook.

Windlas Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Windlas Biotech Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a recent upgrade from Hold to Sell by MarketsMOJO on 4 February 2026, the stock’s price action and technical indicators suggest a cautiously evolving outlook for investors.

Windlas Biotech Ltd has seen a notable shift in its valuation parameters, moving from an attractive to a fair rating, reflecting evolving market perceptions amid a challenging sector backdrop. Despite a modest day gain of 1.90%, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now suggest a more tempered price attractiveness compared to its historical averages and peer group benchmarks.

Windlas Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Windlas Biotech Ltd, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs.699.35, marking a significant decline amid broader market pressures and company-specific performance factors.

Windlas Biotech Ltd has experienced a notable shift in its valuation parameters, moving from an attractive to a fair rating as of early February 2026. This change reflects evolving market perceptions amid a competitive pharmaceutical and biotechnology sector, with key valuation multiples such as price-to-earnings (P/E) and price-to-book value (P/BV) adjusting relative to historical averages and peer benchmarks.

Windlas Biotech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Windlas Biotech Ltd’s shares declined sharply to a new 52-week low of Rs.708.9 on 9 Mar 2026, marking a significant downturn amid broader market weakness and company-specific performance concerns. The stock has underperformed its sector and the broader market over the past year, reflecting subdued financial results and valuation pressures.

Windlas Biotech Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. The stock’s recent price action, combined with mixed signals from MACD, RSI, and moving averages, suggests increasing downside pressure amid a challenging market environment for the Pharmaceuticals & Biotechnology sector.

Windlas Biotech Ltd has recently undergone a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite a downgrade in its overall Mojo Grade to Sell. This change reflects evolving market perceptions amid a challenging pharmaceutical sector landscape, with the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now presenting a more compelling entry point relative to peers and historical averages.

Windlas Biotech Ltd has experienced a subtle but noteworthy shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a recent downgrade in its Mojo Grade from Hold to Sell, the stock’s technical indicators reveal a nuanced picture that investors should carefully analyse amid broader market volatility.

Windlas Biotech Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, prompting a downgrade in its Mojo Grade from Hold to Sell as of 4 February 2026. The stock’s recent price action and technical indicators suggest a bearish trend, with the share price declining 1.92% on 5 March 2026 to close at ₹740.00, down from the previous close of ₹754.45.